Dronedarone/ranolazine - Gilead Sciences

Drug Profile

Dronedarone/ranolazine - Gilead Sciences

Alternative Names: Ranolazine/dronedarone

Latest Information Update: 23 Aug 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Acetanilides; Anti-ischaemics; Benzofurans; Class III antiarrhythmics; Ischaemic heart disorder therapies; Piperazines; Small molecules
  • Mechanism of Action Partial fatty acid oxidation inhibitors; Potassium channel antagonists; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Paroxysmal atrial fibrillation

Most Recent Events

  • 10 May 2014 Final efficacy data from the phase II HARMONY trial in Paroxysmal atrial fibrillation released by Gilead Sciences
  • 31 Mar 2014 Gilead Sciences completes the phase II HARMONY trial in Paroxysmal atrial fibrillation in USA, Germany, Israel, Italy, Netherlands, Poland and United Kingdom (NCT01522651)
  • 27 Jan 2012 Phase-II clinical trials in Paroxysmal atrial fibrillation in USA, Germany, Israel, Italy, Netherlands, Poland and United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top